PharmaResearch Bio announced on the 18th that its botulinum toxin product 'Re N Tox' has obtained item approval from the Thai Food and Drug Administration (TFDA).
Botulinum toxin is a pharmaceutical product extracted from the botulinum bacterium, which, when injected into the skin, microscopically paralyzes the muscles to improve symptoms such as eye twitching and wrinkles.
Thailand is a representative beauty and cosmetic surgery market in Southeast Asia. A company official noted, "This first item approval in Thailand lays the foundation for entering the global market," and added, "We will quickly advance into key countries to strengthen the global competitiveness of 'Re N Tox.'"
PharmaResearch Bio is on the verge of completing its second factory in Gangneung, Gangwon Province, with a total floor area of 7,905 square meters (approximately 2,400 pyeong) and the capacity to produce 6 million vials annually. The company explained that this would enable stable responses to large-scale demand.
PharmaResearch Bio is a subsidiary of PharmaResearch's toxin business and obtained Good Manufacturing Practice (GMP) certification for its dedicated botulinum toxin factory in 2019. It has acquired export permission for the botulinum toxin 'Re N Tox injection' and started supplying to overseas markets. Last year, it completed domestic item approval for the 'Re N Tox injection' 100 unit product and is currently selling it in the domestic market.